158 related articles for article (PubMed ID: 24289638)
1. Determination of HER2 gene amplification in breast cancer using dual-color silver enhanced in situ hybridization (dc- SISH) and comparison with fluorescence ISH (FISH).
Unal B; Karaveli FS; Pestereli HE; Erdogan G
Asian Pac J Cancer Prev; 2013; 14(10):6131-4. PubMed ID: 24289638
[TBL] [Abstract][Full Text] [Related]
2. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer.
Koh YW; Lee HJ; Lee JW; Kang J; Gong G
Mod Pathol; 2011 Jun; 24(6):794-800. PubMed ID: 21317877
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.
Shousha S; Peston D; Amo-Takyi B; Morgan M; Jasani B
Histopathology; 2009 Jan; 54(2):248-53. PubMed ID: 19207950
[TBL] [Abstract][Full Text] [Related]
4. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
[TBL] [Abstract][Full Text] [Related]
5. Delineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.
Carbone A; Botti G; Gloghini A; Simone G; Truini M; Curcio MP; Gasparini P; Mangia A; Perin T; Salvi S; Testi A; Verderio P
J Mol Diagn; 2008 Nov; 10(6):527-36. PubMed ID: 18832456
[TBL] [Abstract][Full Text] [Related]
6. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
7. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
Francis GD; Jones MA; Beadle GF; Stein SR
Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
[TBL] [Abstract][Full Text] [Related]
8. Comparison of HER2 status determination methods in HER2 (2+) patients: Manual fluorescent in situ hybridization (FISH) vs. dual silver enhanced in situ hybridization (SISH).
Pehlivanoglu B; Serin G; Yeniay L; Zekioglu O; Gokmen E; Ozdemir N
Ann Diagn Pathol; 2017 Dec; 31():36-40. PubMed ID: 29146056
[TBL] [Abstract][Full Text] [Related]
9. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
10. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL
Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441
[TBL] [Abstract][Full Text] [Related]
11. Dual-color dual-hapten in situ hybridization (D-DISH) - Comparison with fluorescence in situ hybridization (FISH) for HER2/neu testing in breast cancer.
Gajaria PK; Tambe S; Pai T; Patil A; Desai SB; Shet TM
Indian J Pathol Microbiol; 2020; 63(2):194-199. PubMed ID: 32317514
[TBL] [Abstract][Full Text] [Related]
12. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility.
Papouchado BG; Myles J; Lloyd RV; Stoler M; Oliveira AM; Downs-Kelly E; Morey A; Bilous M; Nagle R; Prescott N; Wang L; Dragovich L; McElhinny A; Garcia CF; Ranger-Moore J; Free H; Powell W; Loftus M; Pettay J; Gaire F; Roberts C; Dietel M; Roche P; Grogan T; Tubbs R
Am J Surg Pathol; 2010 Jun; 34(6):767-76. PubMed ID: 20421783
[TBL] [Abstract][Full Text] [Related]
13. SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.
Jacquemier J; Spyratos F; Esterni B; Mozziconacci MJ; Antoine M; Arnould L; Lizard S; Bertheau P; Lehmann-Che J; Fournier CB; Krieger S; Bibeau F; Lamy PJ; Chenard MP; Legrain M; Guinebretière JM; Loussouarn D; Macgrogan G; Hostein I; Mathieu MC; Lacroix L; Valent A; Robin YM; Revillion F; Triki ML; Seaume A; Salomon AV; de Cremoux P; Portefaix G; Xerri L; Vacher S; Bièche I; Penault-Llorca F
BMC Cancer; 2013 Jul; 13():351. PubMed ID: 23875536
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of silver-enhanced in situ hybridization for evaluating HER2 gene status in invasive breast carcinoma: a comparative study.
Lee Y; Ryu Y; Jeong H; Chang H; Kim Y; Kim A
Arch Med Res; 2012 Feb; 43(2):139-44. PubMed ID: 22475781
[TBL] [Abstract][Full Text] [Related]
15. HER2 status in operable breast cancers from Vietnamese women: Analysis by immunohistochemistry (IHC) and automated silver enhanced in situ hybridization (SISH).
Thang VH; Tani E; Van TT; Krawiec K; Skoog L
Acta Oncol; 2011 Apr; 50(3):360-6. PubMed ID: 21338271
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of reliability of FISH versus brightfield dual-probe in situ hybridization (BDISH) for frontline assessment of HER2 status in breast cancer samples in a community setting: influence of poor tissue preservation.
Schiavon BN; Jasani B; de Brot L; Vassallo J; Damascena A; Cirullo-Neto J; Ivanildo Neves J; Augusto Soares F; Gobbi H; Malagoli Rocha R
Am J Surg Pathol; 2012 Oct; 36(10):1489-96. PubMed ID: 22982892
[TBL] [Abstract][Full Text] [Related]
17. Concomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplification.
Varga Z; Tubbs RR; Moch H
PLoS One; 2014; 9(8):e105961. PubMed ID: 25153153
[TBL] [Abstract][Full Text] [Related]
18. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
Pala EE; Bayol U; Ozguzer A; Akman O
Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
[TBL] [Abstract][Full Text] [Related]
19. [HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH)].
Akhdar A; Bronsard M; Lemieux R; Geha S
Ann Pathol; 2011 Dec; 31(6):472-9. PubMed ID: 22172120
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of analytical accuracy of HER2 status in patients with breast cancer: Comparison of HER2 GPA with HER2 IHC and HER2 FISH.
Jensen SG; Thomas PE; Christensen IJ; Balslev E; Hansen A; Høgdall E
APMIS; 2020 Nov; 128(11):573-582. PubMed ID: 32860265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
